TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT04792034: Pharmacokinetics, Safety, and Tolerability Study of GOPRELTO® Nasal Solution and NUMBRINO™ Nasal Solution

Sponsor: LXO Ireland · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 40 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$1,555,752

Rescue Site Savings

+$1,037,168

Unlock Full NCT04792034 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04792034 Rescue Dossier →